Skip to Content
MilliporeSigma
All Photos(1)

Documents

Y0001465

Apomorphine hydrochloride hemihydrate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

R-(−)-Apomorphine hydrochloride hemihydrate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
C17H17NO2 · HCl · 1/2H2O
CAS Number:
41372-20-7
Molecular Weight:
312.79
MDL number:
MFCD00150904
UNSPSC Code:
41116107
PubChem Substance ID:
329831436
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

apomorphine

manufacturer/tradename

EDQM

mp

285-287 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Cl[H].Cl[H].[H]O[H].[H][C@]12Cc3ccc(O)c(O)c3-c4cccc(CCN1C)c24.[H][C@]56Cc7ccc(O)c(O)c7-c8cccc(CCN5C)c68

InChI

1S/2C17H17NO2.2ClH.H2O/c2*1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12;;;/h2*2-6,13,19-20H,7-9H2,1H3;2*1H;1H2/t2*13-;;;/m11.../s1

InChI key

CXWQXGNFZLHLHQ-DPFCLETOSA-N

Gene Information

human ... DRD2(1813) , DRD3(1814) , DRD4(1815)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Apomorphine hydrochloride hemihydrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

2024 CiteAb Award Winner for Supplier Succeeding in Parkinson′s Research
Sales restrictions may apply.

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H301

Precautionary Statements

P301 + P330 + P331 + P310

Hazard Classifications

Acute Tox. 3 Oral

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Robert A Hauser et al.
Parkinsonism & related disorders, 20(11), 1171-1176 (2014-09-23)
Nausea and vomiting can occur in Parkinson's disease (PD) patients initiated on apomorphine subcutaneous injections and antiemetic prophylaxis is recommended per product labeling. Data suggest long-term antiemetic prophylaxis may not be needed, although this has not been systematically studied. We
Recep Dokuyucu et al.
International journal of clinical and experimental medicine, 7(10), 3354-3361 (2014-11-25)
Tetracycline antibiotic drug minocycline has strongly neuroprotective and anti-inflammatory effects. Minocycline has also remarkable brain tissue penetration, is clinically entirely tolerated and properly absorbed when taken orally. In our study, we class with the effects of minocycline and chlorpromazine, a
Tugba Goktalay et al.
Progress in neuro-psychopharmacology & biological psychiatry, 53, 54-60 (2014-03-19)
Varenicline, a widely used smoking cessation drug, has partial agonistic activity at α4β2 nicotinic receptors, and full agonistic activity at α7 nicotinic receptors. Thus it may interact with cognitive processes and may alleviate some of the cognitive disturbances observed in
Ngoc B Lu-Nguyen et al.
Human gene therapy, 25(7), 631-641 (2014-03-19)
Standard integration-proficient lentiviral vectors (IPLVs) are effective at much lower doses than other vector systems and have shown promise for gene therapy of Parkinson's disease (PD). Their main drawback is the risk of insertional mutagenesis. The novel biosafety-enhanced integration-deficient lentiviral
Reza Sedaghat et al.
Iranian journal of pharmaceutical research : IJPR, 13(1), 227-234 (2014-04-16)
Parkinson disease (PD) is the most common movement disorder with progressive degeneration of midbrain dopaminergic neurons for which current treatments afford symptomatic relief with no-prevention of disease progression. Due to the neuroprotective property of the Nigella sativa bioactive compound thymoquinone
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service